

Lavinia Morosi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7804082/publications.pdf>

Version: 2024-02-01

44
papers

1,512
citations

394421
19
h-index

315739
38
g-index

44
all docs

44
docs citations

44
times ranked

2562
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging. <i>Talanta</i> , 2022, 237, 122918.	5.5	9
2	THE SPACE DIMENSION AT THE MICRO LEVEL: MASS SPECTROMETRY IMAGING OF DRUGS IN TISSUES. <i>Mass Spectrometry Reviews</i> , 2021, 40, 201-214.	5.4	16
3	Preformed Biodegradable Zwitterionic Nanoparticles as Tunable Excipients for the Formulation of Therapeutics Directly at the Point of Care. <i>Industrial & Engineering Chemistry Research</i> , 2021, 60, 10699-10709.	3.7	6
4	Chemical Images on Fingerprints Revealed with Mass Spectrometry. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 5624.	2.5	1
5	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 286.	8.6	18
6	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021, 103-104, 22-36.	3.6	2
7	Betulinic acid and its spray dried microparticle formulation: In vitro PDT effect against ovarian carcinoma cell line and in vivo plasma and tumor disposition. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021, 224, 112328.	3.8	2
8	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. <i>International Journal of Biological Sciences</i> , 2020, 16, 1363-1375.	6.4	22
9	A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data. <i>GigaScience</i> , 2020, 9, .	6.4	5
10	Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e59.	2.2	25
11	Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs. <i>Pharmaceutics</i> , 2019, 11, 658.	4.5	17
12	Abstract 198: The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature. , 2019, , .		0
13	Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin. <i>Journal of Controlled Release</i> , 2018, 276, 140-149.	9.9	12
14	Drug-Homogeneity Index in Mass-Spectrometry Imaging. <i>Analytical Chemistry</i> , 2018, 90, 13257-13264.	6.5	6
15	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. <i>Analytica Chimica Acta</i> , 2018, 1042, 1-10.	5.4	7
16	Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients. <i>Macromolecular Bioscience</i> , 2018, 18, e1800164.	4.1	9
17	High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation. <i>Pharmaceutical Research</i> , 2017, 34, 1180-1186.	3.5	20
18	Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 1-12.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Poly(HPMA)-based copolymers with biodegradable side chains able to self assemble into nanoparticles. RSC Advances, 2017, 7, 50981-50992.	3.6	24
20	Application of 3D Mass Spectrometry Imaging to TKIs. Clinical Pharmacology and Therapeutics, 2017, 102, 748-751.	4.7	17
21	Self-Assembling amphiphilic block copolymer from renewable ̵-decalactone and ̵-dodecalactone. Journal of Polymer Science Part A, 2017, 55, 3788-3797.	2.3	7
22	Heteronanoparticles by self-Assembly of Doxorubicin and Cycloamine Conjugates. ACS Medicinal Chemistry Letters, 2017, 8, 953-957.	2.8	15
23	Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release. ACS Nano, 2017, 11, 9413-9423.	14.6	44
24	A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging. Nanomaterials, 2017, 7, 71.	4.1	13
25	Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PLoS ONE, 2017, 12, e0186250.	2.5	52
26	Abstract 174: Preclinical activity of new liposomal formulation of doxorubicin (TLD-1). , 2017, , .		0
27	Self-Assembling amphiphilic <scp>PEG</scp>ylated block copolymers obtained through <scp>RAFT</scp> polymerization for drug delivery applications. Journal of Applied Polymer Science, 2016, 133, .	2.6	13
28	Influence of the polymer structure over self-assembly and thermo-responsive properties: The case of PEG- β -PCL grafted copolymers via a combination of RAFT and ROP. Journal of Polymer Science Part A, 2016, 54, 2919-2931.	2.3	25
29	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Scientific Reports, 2016, 6, 39284.	3.3	68
30	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. Scientific Reports, 2016, 6, 37027.	3.3	58
31	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics, 2016, 13, 40-46.	4.6	31
32	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Molecular Cancer Therapeutics, 2016, 15, 125-135.	4.1	56
33	Abstract 3377: Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy. Cancer Research, 2016, 76, 3377-3377.	0.9	2
34	Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. British Journal of Cancer, 2015, 112, 306-312.	6.4	86
35	Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Clinical Pharmacology and Therapeutics, 2014, 96, 224-238.	4.7	60
36	Urinary exosomes and diabetic nephropathy: a proteomic approach. Molecular BioSystems, 2013, 9, 1139.	2.9	61

#	ARTICLE	IF	CITATIONS
37	Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. Current Opinion in Pharmacology, 2013, 13, 807-812.	3.5	26
38	Differential protein profiling of renal cell carcinoma urinary exosomes. Molecular BioSystems, 2013, 9, 1220.	2.9	138
39	Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging. PLoS ONE, 2013, 8, e72532.	2.5	54
40	Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Molecular BioSystems, 2012, 8, 1040.	2.9	28
41	Protein profiling of microdomains purified from renal cell carcinoma and normal kidney tissue samples. Molecular BioSystems, 2012, 8, 1007-1016.	2.9	13
42	A hyphenated microLC-ESI-TOF-MS platform for exosomal lipidomics investigations: Application to RCC urinary exosomes. Electrophoresis, 2012, 33, 689-696.	2.4	91
43	Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics, 2011, 11, 709-720.	2.2	280
44	Human sialidase NEU4 long and short are extrinsic proteins bound to outer mitochondrial membrane and the endoplasmic reticulum, respectively. Glycobiology, 2010, 20, 148-157.	2.5	55